| Literature DB >> 33263620 |
Yiwei Yan1, Lian Jiang1, Mei Li1, Huifen Zhang1, Ying Shen1, Wenhao Zhang1, Wenting Zhang1.
Abstract
OBJECTIVES: To evaluate the diagnostic value of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and the MMP-9/TIMP-1 ratio in fetal inflammatory response syndrome (FIRS), and determine a possible association with the incidence of bronchopulmonary dysplasia (BPD) and myocardial injury.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33263620 PMCID: PMC7654901 DOI: 10.6061/clinics/2020/e2049
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
General characteristics of the two groups.
| FIRS group (n=61) | Control group (n=57) | t/F value |
| |
|---|---|---|---|---|
| Male/Female (n) | 32/29 | 30/27 | 0.00 | 0.99 |
| Gestational age (weeks) | 29.35±1.44 | 29.29±1.51 | 0.22 | 0.83 |
| Birth weight (g) | 1489±178 | 1482±169 | 0.22 | 0.83 |
| Apgar score at 1 min | 7.28±1.42 | 7.32±1.34 | 0.16 | 0.88 |
| Apgar score at 5 min | 8.39±1.52 | 8.43±1.45 | 0.15 | 0.88 |
| Apgar score at 10 min | 9.01±1.26 | 9.12±1.32 | 0.46 | 0.64 |
FIRS, Fetal inflammatory response syndrome.
Levels of IL-6, MMP-9, and TIMP-1, and the MMP-9/TIMP-1 ratio in the different groups.
| IL-6 (pg/L) | MMP-9 (ng/L) | TIMP-1 (ng/L) | MMP-9 / TIMP-1 ratio (%) | |
|---|---|---|---|---|
| Control group 1 | 4.39±0.99 | 1.68±0.46 | 12.57±2.00 | 13.77±4.37 |
| FIRS group 1 | 42.68±6.98 | 48.48±10.2 | 106.07±6.61 | 45.95±10.96 |
| Control group 2 | 4.51±1.03 | 4.80±1.51 | 60.93±7.37 | 7.92±2.45 |
| FIRS group 2 | 33.63±8.77 | 34.94±11.08 | 99.97±17.38 | 35.04±9.00 |
FIRS, Fetal inflammatory response syndrome; IL-6, interleukin 6; MMP-9, matrix metallopeptidase 9; TIMP-1, tissue inhibitor matrix metalloproteinase 1;
indicates p<0.01 compared with Control group 1;
indicates p<0.01 compared with Control group 2.
Figure 1The correlation between IL-6 and MMP-9, TIMP-1, and the MMP-9/TIMP-1 ratio in preterm infants. (A) Spearman’s linear correlation results indicate that IL-6 was positively correlated with MMP-9. (B) Spearman’s linear correlation results indicate that IL-6 was positively correlated with TIMP-1; (C) Spearman’s linear correlation results indicate that IL-6 was positively correlated with the MMP-9/TIMP-1 ratio. IL-6, interleukin 6; MMP-9, matrix metallopeptidase 9; TIMP-1, tissue inhibitor matrix metalloproteinase 1.
The diagnostic value of cytokines for predicting FIRS.
| Cutoff value | Sensitivity (%) | Specificity (%) | 95% CI | AUC | |
|---|---|---|---|---|---|
| MMP-9 | 21.61 | 0.98 | 0.91 | 0.86-0.98 | 0.92 |
| TIMP-1 | 78.76 | 0.94 | 0.91 | 0.83-0.97 | 0.90 |
| MMP-9 / TIMP-1 ratio | 22.50 | 0.96 | 0.90 | 0.90-0.99 | 0.95 |
FIRS, Fetal inflammatory response syndrome; CI, Confidence interval; AUC, Area under the curve; IL-6, interleukin 6; MMP-9, matrix metallopeptidase 9; TIMP-1, tissue inhibitor matrix metalloproteinase 1.
Figure 2Histological changes in placental tissues obtained from preterm infants were examined by HE staining. (A) Normal placental tissue from preterm infants demonstrates no obvious pathological change (×200). (B) Chorionic membrane tissue demonstrates mild inflammatory cell infiltration (×200). (C) Acute inflammatory placental tissues show congestion and edema, with aggregated neutrophils (×200). (D) Chronic inflammatory placental tissues show necrosis, proliferation, neutrophils, lymphocytes, and monocytes (×200). HE, hematoxylin and eosin.
Figure 3Examination of amniotic fluid smears of preterm infants. (A) The amniotic fluid smear for normal preterm infants mainly shows exfoliated epithelial cells and a small number of impurities (×400). (B) The amniotic fluid smear for preterm infants with FIRS shows inflammatory cells, mostly including neutrophils and a few aggregated lymphocytes (×400). (C) Images of the amniotic fluid smear for preterm infants with FIRS were captured using oil immersion microscopy. FIRS, fetal inflammatory response syndrome.
The incidence of BPD in the different groups.
| Occurrence (n) | Nonoccurrence (n) | Total (n) | Rate (%) | |
|---|---|---|---|---|
| Control group 1 | 2 | 23 | 25 | 8.00 |
| FIRS group 1 | 10 | 23 | 33 | 30.30 |
| Control group 2 | 0 | 32 | 32 | 0 |
| FIRS group 2 | 1 | 27 | 28 | 3.57 |
BPD, Bronchopulmonary dysplasia; FIRS, Fetal inflammatory response syndrome;
indicates p<0.05 compared with Control group 1;
indicates p<0.01 compared with FIRS group 1.
The incidence of myocardial damage in the different groups.
| Occurrence (n) | Nonoccurrence (n) | Total (n) | Rate (%) | |
|---|---|---|---|---|
| Control group 1 | 2 | 23 | 25 | 8.00 |
| FIRS group 1 | 11 | 22 | 33 | 33.33 |
| Control group 2 | 1 | 31 | 32 | 3.13 |
| FIRS group 2 | 6 | 22 | 28 | 21.43 |
FIRS, Fetal inflammatory response syndrome;
indicates p<0.05 compared with Control group 1;
indicates p<0.05 compared with Control group 2.